beta-2 Microglobulin antibody
Quick Overview for beta-2 Microglobulin antibody (ABIN6296289)
Target
See all beta-2 Microglobulin (B2M) AntibodiesReactivity
Host
Clonality
Conjugate
Application
-
-
Purpose
- Mouse anti-Human/non-Human primates Beta-2 Microglobulin Antibody [Sodium Azide Free]
-
Specificity
- Cytoplasmic
-
Purification
- Full length recombinant human B2M protein was used as the immunogen for the Beta-2 Microglobulin antibody.
-
Immunogen
- Full length recombinant human B2M protein was used as the immunogen for the Beta-2 Microglobulin antibody.
-
-
-
-
Application Notes
-
Flow Cytometry: 0.5-1 μg/million cells in 0.1ml
Immunofluorescence: 0.5-1 μg/mL
Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 min at RT (1)
Prediluted format: incubate for 30 min at RT (2) -
Restrictions
- For Research Use only
-
-
-
Buffer
- In 1X PBS, BSA free, sodium azide free
-
Preservative
- Azide free
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- 2-8°C. The azide-free format should be aliquoted and stored at -20°C or colder.
-
-
- beta-2 Microglobulin (B2M) (beta-2-Microglobulin (B2M))
-
Alternative Name
- Beta-2-microglobulin
-
Background
-
Target Description: Beta-2 microglobulin is a 12KDa protein with a pI of 5.6. Serum beta2 microglobulin levels are a reflection of cell turnover. Levels rise with fever, inflammation, and infection. Increased serum levels are also seen in B-cell malignancies and in renal failure and may indicate a worse prognosis for patients with early-stage Hodgkin's lymphoma. In urine, increased levels are seen in proximal renal tubular disease as well as renal transplant rejection. Beta-2 microglobulin levels can rise either because its rate of synthesis has increased (e.g. in AIDS, malignant monoclonal plasma cell dyscrasia, solid tumours and autoimmune disease) or because of impaired renal filtration (e.g. due to renal insufficiency, graft rejection or nephrotoxicity induced by post-transplantation immunosuppressive therapy).
Gene Symbol: B2M///CDABP0092///HDCMA22P
-
Gene ID
- 567
-
UniProt
- P61769
-
Pathways
- TCR Signaling, Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process
Target
-